dpp 4 and glp 1 together dpp-4_inhibitors [TUSOM How does sitagliptin work? DPP-4

Description

The findings indicate that: 67% of Omada members were persistent on their medication at one year and experienced weight loss comparable to clinical trials Average weight loss at one year in the program was 18.4% for members persistent on medication and 13.1% for members who discontinued before one year In terms of engagement, members completed more than 10 actions a week on average This data suggests that providing the right kind of support to promote GLP-1 persistence can help patients achieve clinical trial-level weight loss, setting the stage for cardiometabolic disease risk reduction

JAMA 327 , 17041706 (2022)

Pharmaceutical companies should warn people about dangerous, unexpected side effects from their drugs, and many people believe that Novo Nordisk did not do enough to warn the public